Zoetis ZTS Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Business | |||||
| International | $4.23B+3.1% | $4.1B+4.9% | $3.91B+6.2% | $3.68B+0.8% | |
| U.S. | $5.1B+0.5% | $5.07B+11.4% | $4.56B+5.6% | $4.31B+6.7% | |
| Revenue by Product | |||||
| Animal health diagnostics | $435M+12.7% | $386M+2.7% | $376M+6.5% | $353M-5.6% | |
| Anti-infectives | $1.03B-6.8% | $1.1B+4.1% | $1.06B-2.2% | $1.08B-11.0% | |
| Cattle | $1.48B-3.7% | $1.53B+1.9% | $1.5B+4.4% | $1.44B-7.5% | |
| Contract manufacturing & human health | $117M+46.3% | $80M+2.6% | $78M-9.3% | $86M+4.9% | |
| Dermatology | $1.74B+5.3% | $1.66B+16.0% | $1.43B+7.4% | $1.33B+12.6% | |
| Fish | $288M+19.0% | $242M+10.0% | $220M+3.8% | $212M+13.4% | |
| Horses | $6.28B+4.8% | $5.99B+13.3% | $5.29B+7.1% | $4.94B+11.6% | |
| Other Non Pharmaceuticals | $268M+5.9% | $253M-0.4% | $254M+1.6% | $250M+8.2% | |
| Other pharmaceutical | $696M+5.8% | $658M-2.9% | $678M— | —— | |
| Pain and sedation | $837M-1.6% | $851M+41.4% | $602M+43.3% | $420M— | |
| Parasiticides | $2.35B+9.2% | $2.15B+10.6% | $1.95B+4.7% | $1.86B+13.8% | |
| Poultry | $432M-18.0% | $527M+0.6% | $524M+10.1% | $476M-6.1% | |
| Sheep and other | $91M+11.0% | $82M-18.0% | $100M+2.0% | $98M+3.2% | |
| Swine | $460M-10.9% | $516M-5.0% | $543M-3.9% | $565M-14.3% | |
| Vaccines | $1.95B+6.8% | $1.83B+3.2% | $1.77B+3.1% | $1.72B+2.7% | |
| Revenue by Geography | |||||
| Australia | $333M+4.4% | $319M-1.2% | $323M+11.8% | $289M+11.6% | |
| Brazil | $386M-6.8% | $414M+5.3% | $393M+19.1% | $330M+5.8% | |
| Canada | $293M+5.8% | $277M+8.6% | $255M+7.1% | $238M+2.6% | |
| Chile | $140M+13.8% | $123M-12.1% | $140M-0.7% | $141M+3.7% | |
| China | $222M-17.8% | $270M-15.6% | $320M-16.2% | $382M+7.0% | |
| France | $164M+5.1% | $156M+9.9% | $142M+12.7% | $126M-4.5% | |
| Germany | $240M+6.7% | $225M+11.4% | $202M+14.8% | $176M-3.8% | |
| Italy | $138M+7.0% | $129M+6.6% | $121M+9.0% | $111M-3.5% | |
| Japan | $150M+2.0% | $147M-7.0% | $158M-8.7% | $173M-7.0% | |
| Mexico | $158M-6.5% | $169M+4.3% | $162M+19.1% | $136M+2.3% | |
| Other developed markets | $641M+13.7% | $564M+10.2% | $512M+9.4% | $468M+0.2% | |
| Other emerging markets | $903M+4.4% | $865M+10.3% | $784M+3.4% | $758M-2.6% | |
| Spain | $141M+8.5% | $130M+6.6% | $122M+3.4% | $118M-7.8% | |
| Total geographical area | $9.33B+1.7% | $9.18B+8.4% | $8.47B+5.9% | $7.99B+3.9% | |
| United Kingdom | $322M+2.5% | $314M+13.4% | $277M+17.9% | $235M+0.4% | |
| United States | $5.1B+0.5% | $5.07B+11.4% | $4.56B+5.6% | $4.31B+6.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Zoetis break its business down?
- Zoetis (ZTS) reports revenue by business across 2 parts — International and U.S.. Each is extracted from the segment footnotes and tracked over time.
- Where does Zoetis's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zoetis's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
